Table 2.
Adjusted, interval-specific effects of 2020 versus the forecast of 2020 on the incidence of eGFR <10 ml/min per 1.73 m2 and PD utilization among all patients who initiated dialysis and the incidence of catheter utilization among all patients who initiated hemodialysis
| Weeks | Absolute Effect, Difference (95% CI)a | Relative Effect, OR (95% CI)b |
|---|---|---|
| Percentage of dialysis patients with eGFR <10 ml/min per 1.73 m2 | ||
| Weeks 3–6 | 0.01 (−1.20 to 1.22) | 1.00 (0.95 to 1.05) |
| Weeks 7–10 | 0.48 (−0.73 to 1.70) | 1.02 (0.97 to 1.08) |
| Weeks 11–14 | 1.14 (−0.16 to 2.40) | 1.05 (0.99 to 1.11) |
| Weeks 15–18 | 1.74 (0.41 to 3.07) | 1.08 (1.02 to 1.15) |
| Weeks 19–22 | 2.86 (1.57 to 4.16) | 1.14 (1.07 to 1.20) |
| Weeks 23–36 | 2.31 (1.03 to 3.59) | 1.11 (1.05 to 1.17) |
| Percentage of dialysis patients performing PD | ||
| Weeks 3–6 | 0.40 (−0.35 to 1.15) | 1.05 (0.96 to 1.13) |
| Weeks 7–10 | 0.95 (0.18 to 1.72) | 1.11 (1.03 to 1.20) |
| Weeks 11–14 | 2.33 (1.50 to 3.17) | 1.24 (1.14 to 1.34) |
| Weeks 15–18 | 1.79 (0.93 to 2.66) | 1.17 (1.07 to 1.27) |
| Weeks 19–22 | 0.03 (−0.79 to 0.86) | 1.00 (0.92 to 1.09) |
| Weeks 23–36 | 1.13 (0.30 to 1.96) | 1.09 (1.01 to 1.18) |
| Percentage of hemodialysis patients with a CVC | ||
| Weeks 3–6 | −1.06 (−2.08 to −0.04) | 0.94 (0.87 to 1.00) |
| Weeks 7–10 | −0.55 (−1.57 to 0.47) | 0.97 (0.91 to 1.04) |
| Weeks 11–14 | 0.84 (−0.25 to 1.92) | 1.07 (0.99 to 1.15) |
| Weeks 15–18 | 3.34 (2.25 to 4.44) | 1.30 (1.20 to 1.41) |
| Weeks 19–22 | 1.05 (−0.04 to 2.14) | 1.08 (1.00 to 1.17) |
| Weeks 23–36 | 0.04 (−1.05 to 1.13) | 1.00 (0.93 to 1.08) |
“Forecast” of 2020 based on the secular trends of 2017–2019 continuing into 2020.
a
Percentage differences estimated from LPRMs.
b
ORs estimated from logistic regression models.